• Home
• About
  • About Lipaglyn
  • About Zydus
  • About ZRC
• Doctors
• Patients
• Health Blog
• FAQs
• News Room
• Updates
• Events
• Contact us

Novel drug to treat Diabetic Dyslipidemia – a global, unmet healthcare need

Novel NCE from an Indian research pipeline to move from the lab to the market

A Novel Therapy to treat Diabetic Dyslipidemia

Zydus becomes the 1st Indian Pharma Company to launch an NCE

It’s first-of-its kind novel action works as a lipid regulator and also provides glycemic benefits

This marks the beginning of India’s contribution to the world of drug discovery

LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia

combines lipid and glucose lowering effects in one single molecule.

Diabetic Dyslipidemia

Diabetic Dyslipidemia is a condition where a person is diabetic and has elevated levels of the total cholesterol

About Lipaglyn

Lipaglyn™ is the first NCE discovered and developed indigenously by an Indian Pharma Company.

How it Works?

Lipaglyn™ is a first-in-class drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in type 2 diabetes

Key Milestones

The journey of Lipaglyn from concept to market

Photo Gallery

‹ ›

Disclaimer : Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.